


Cell Line	Tumor type	RAS/BRAF mutation status
A549	Lung	KRASmut G12S
TOV21g	Ovarian	KRASmut G13C
SKMEL5	Melanoma	BRAF mut V600E
IGR-1	Melanoma	BRAFmut V600E
WM115	Melanoma	BRAF mut V600E

FIG. 1



Tumor growth
Tumor volume
(mm3 +/- SEM)
1200
1000
800
600
400
200
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Days on treatment

FIG. 2A




Response at Day 13
% Change in Tumor Volume
400
300
200
100
0
-100

FIG. 2B



Group	Median survival (days)	Tumor free mice (day 95)
Vehicle	20	0/10
VS-6766	37.5	0/10
Anti-PD-1	30.5	0/10
VS-6766 + anti-PD-1	43	3/10

FIG. 2C




FIG. 3A



Effector Memory CD4 cells
- Spleen -
CD3+ CD4+ CD44+ CD62L+ cells% in live CD45+ CD3+ CD4+ cells
60
40
20
0
**
Naive
VS-6766/PD1
Effector Memory CD8 cells
- Spleen -
CD3+ CD8+ CD44+ CD62L+ cells% in live CD45+ CD3+ CD8+ cells
25
20
15
10
5
0
**
Naive
VS-6766/PD1

FIG. 3B



Tumor growth
- VS-6766 + VS-4718 + anti-PD-1 -
Tumor volume (mm3 +/- SEM)
1200
1000
800
600
400
200
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Days on treatment
Vehicle
VS-6766 0.5 mg/kg QD
anti-PD-1 3 mg/kg 2xW
VS-6766 + anti-PD-1
VS-6766 + VS-4718 + anti-PD-1

FIG. 4A



Tumor growth
- VS-6766 + VS-4718 + anti-PD-1-
Tumor volume (mm3 +/- SEM)
1400
1200
1000
800
600
400
200
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Days on treatment
Vehicle
VS-6766 0.5 mg/kg QD
VS-4718 50 mg/kg
VS-6766 + VS-4718
VS-6766 + VS-4718 + anti-PD-1

FIG. 4B